Category Featured

Cranbury Pharmaceuticals Gains FDA Approval for Generic Emflaza® Oral Suspension (Deflazacort) for Duchenne Muscular Dystrophy

Cranbury Pharmaceuticals (Cranbury), a wholly-owned subsidiary of Tris Pharma, has announced that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Application (ANDA) for the first generic version of Emflaza® oral suspension (deflazacort). This medication is…

Read MoreCranbury Pharmaceuticals Gains FDA Approval for Generic Emflaza® Oral Suspension (Deflazacort) for Duchenne Muscular Dystrophy

WHO Member States to Share Historic IHR, Pandemic Agreement Outcomes at World Health Assembly

After intensive negotiations, WHO Member States have concluded discussions aimed at enhancing global readiness for future pandemics and outbreaks following the COVID-19 crisis. They have agreed to present the outcomes of their efforts for deliberation at the upcoming World Health…

Read MoreWHO Member States to Share Historic IHR, Pandemic Agreement Outcomes at World Health Assembly

Hansoh Pharma Enhances Collaboration with Biotheus to Advance Development of EGFR/cMET Bispecific Antibody-Drug Conjugates

Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma, 03692.HK), a leading innovative pharmaceutical company in China, and Biotheus Inc. (Biotheus), a clinical-stage biotech company specializing in biologics for oncology and inflammatory diseases, have jointly announced an expansion of their strategic partnership.…

Read MoreHansoh Pharma Enhances Collaboration with Biotheus to Advance Development of EGFR/cMET Bispecific Antibody-Drug Conjugates